- The Wall Street Journal•6 minutes ago
Teva Pharmaceutical Industries Ltd. on Wednesday won regulatory approval from the Federal Trade Commission for its acquisition of Allergan PLC’s generics business, conditioned upon Teva’s divestiture of ...
- American City Business Journals•17 minutes ago
The Federal Trade Commission on Wednesday gave its approval to Teva Pharmaceutical Industries Ltd.’s proposed $40.5B acquisition of Allergan’s generics business. The approval was granted after Teva agreed to divest more than 75 generic drugs to rival businesses — marking the largest drug divestiture order in an FTC pharmaceutical merger case. “Millions of Americans rely daily on generic drugs to treat a wide range of illnesses,” said Debbie Feinstein, director of the FTC’s Bureau of Competition.
|Bid||55.10 x 600|
|Ask||55.11 x 200|
|52wk Range||48.01 - 71.78|
|Day's Range||54.28 - 55.23|
|Avg Vol (3m)||6,193,850|
As of 3:46 PM EDT. NYSE Real Time Price. Market open.